One step closer to a cure for preeclampsia? Boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1
Hlavní autoři: | Cerdeira, AS, Vatish, M, Lecarpentier, E |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Lippincott, Williams & Wilkins
2020
|
Podobné jednotky
-
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
Autor: Kifle, MM, a další
Vydáno: (2022) -
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
Autor: Meron M. Kifle, a další
Vydáno: (2022-06-01) -
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Autor: Natalie J. Hannan, a další
Vydáno: (2017-05-01) -
Differences in levelFms-Like Tyrosine Kinase-1 (sFlt-1), soluble Endoglin (s-Eng), and Placental Growth Factor (PIGF) between Early Onset Preeclampsia and Late Onset Preeclampsia
Autor: Lita Nafratilova, a další
Vydáno: (2018-10-01) -
The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience
Autor: Andrijana Müller, a další
Vydáno: (2019-02-01)